Download the Visual
Big pharma needs launches worth about $2.8 billion in peak sales
To hit a 7.5% market-cap growth target, big pharma needs each new drug launch to carry about $2.8 billion in annual peak sales potential. That is the bar in Sleuth’s directional February 2024 model of the top 10 pharma companies, excluding Eli Lilly and Novo Nordisk. It helps explain why pharma concentrates on the largest markets and why many small- and mid-cap biotechs struggle to find a buyer.
The model rests on consensus estimates, February 2024 market capitalizations and simple assumptions, so its output is an order-of-magnitude bar, not a forecast.
Pharma’s cost structure turns small revenue gains into large profit gains
For the top 10 excluding Lilly and Novo Nordisk, consensus estimates in February 2024 had revenue rising 3.5% in 2025, from about $412 billion to $427 billion, and net income rising 8.2%, from about $130 billion to $141 billion. Once R&D, manufacturing and sales force costs are covered, added volume flows largely to profit.
That leverage is why pharma favors late-stage assets that bolt onto existing commercial infrastructure: the best use of the engine is to add volume to it.
How the model gets from market cap to a $2.8 billion bar
The model excludes Lilly and Novo Nordisk, worth about $727 billion and $546 billion in February 2024, as outliers after the GLP-1 run-up. It then works in five steps:
- Growth target. Growing the other eight companies’ combined market cap of about $2 trillion by 7.5% requires about $150 billion of new value.
- New assets’ share. Assuming 20% comes from existing assets that outperform leaves $120 billion for new assets.
- Revenue needed. The group traded at 4.6 times estimated 2025 net sales, a blend of fast-growing and mature products. Valuing mature sales at 2x and assigning the rest of the market cap to products expected to grow more than 10% a year from 2023 to 2026 implies 9.1 times 2025 high-growth sales, so $120 billion of value needs about $13 billion of new revenue.
- Loss-of-exclusivity (LOE) replacement. Sleuth’s LOE data showed a run rate of about $36 billion a year in a period that includes the Humira and Keytruda expiries, against a historical average of about $10 billion. The model uses $15 billion, for an annual revenue gap of about $28 billion.
- Launches. The 10 companies had 14, 8 and 17 new drug approvals in 2021, 2022 and 2023, and their per-company medians sum to about 10 a year (nine excluding Lilly and Novo Nordisk). Spreading $28 billion across 10 launches gives $2.8 billion of peak sales each.
Peak sales are a quick read of an asset’s commercial ceiling, though Sleuth’s look at how far five-year drug sales forecasts miss shows how uncertain they are. Any change in the inputs moves the bar.
What the hurdle means for pharma strategy and biotech M&A
Sleuth’s interpretation of the model, as of February 2024:
- Pharma chases mega-markets. Once competition is factored in, only the largest markets offer the scale the model demands.
- Many SMID-cap biotechs are stuck in no man’s land. Assets with less than $1 billion in peak sales potential do not move the needle enough to justify an acquisition, so their owners need a clean fit with an existing commercial structure or added scale, for example through a merger of equals, the dynamic behind biotech’s consolidation problem.
- Pharma runs a venture-style portfolio. That leaves gaps for patients where the opportunity is too small for pharma, which smaller companies can fill if they assemble enough scale.
In 2026, most top-pharma buyouts were early bets rather than bought revenue: in Sleuth’s T15 pharma buyout map, Phase 1 was the most common stage at announcement, and Lilly made 13 of the 29 buyouts through early September.
Revenue and net income are consensus estimates for 2024 and 2025, market capitalizations are as of February 2024, and approval counts cover 2021 to 2023. The $2.8 billion hurdle is a directional estimate from February 2024, and this page is a dated snapshot. The 2026 buyout figures are as of early September 2026.
Frequently asked questions about pharma’s blockbuster hurdle
How much peak sales does a new drug need to matter to big pharma?
About $2.8 billion a year, in Sleuth’s February 2024 directional model of the top 10 pharma companies excluding Lilly and Novo Nordisk. The figure spreads about $28 billion of annual revenue to add and replace across about 10 launches a year.
How did Sleuth calculate the $2.8 billion figure?
The February 2024 model took a 7.5% growth target on about $2 trillion of market cap, assigned $120 billion of that value to new assets, converted it to about $13 billion of revenue at 9.1x, added $15 billion of annual LOE replacement and divided the $28 billion by about 10 launches.
Why did the model exclude Eli Lilly and Novo Nordisk?
Their valuations had run up on GLP-1 expectations. In February 2024 they were worth about $727 billion and $546 billion, with 2025 revenue growth estimates of 17.7% and 17.1%, against 3.5% for the other eight combined.
Why do mid-size biotech assets struggle to attract pharma buyers?
In Sleuth’s February 2024 view, assets with less than $1 billion in peak sales potential are too small to move a big pharma company’s growth, so they need a clean fit with an existing commercial structure or added scale, such as a merger of equals.
